AJH: Cerebral venous thrombosis and myeloproliferative tumors: a three-center study of 74 consecutive cases

Cerebral venous thrombosis (CVT) is a rare event with an estimated incidence of 15.
7 cases per million per year in the general population
.

Cerebral venous thrombosis occurs in <1% of patients with myeloproliferative tumor (MPN), but overall, the obvious MPN is the underlying disease in 3.

Cerebral venous thrombosis (CVT) is a rare event with an estimated incidence of 15.

The recent association between cerebral venous thrombosis (CVT) and COVID-19 vaccination also prompted researchers to investigate 74 cases of CVT associated with myeloproliferative tumors (MPN) (median age = 44 years, range 15-85; 61%) Women) conduct a retrospective review

the purpose of research:

1) Estimate the incidence of CVT in the context of MPN subtypes, and then describe the clinical phenotype and treatment strategy;

1) Estimate the incidence of CVT in the context of MPN subtypes, and then describe the clinical phenotype and treatment strategy; 1) Estimate the incidence of CVT in the context of MPN subtypes, and then describe the clinical phenotype and treatment strategy;

(2) Determine the long-term prospects of patients with MPN and CVT from the aspects of recurrent thrombosis, major bleeding events, neurological sequelae and survival rate;

(2) Determine the long-term prospects of patients with MPN and CVT from the aspects of recurrent thrombosis, major bleeding events, neurological sequelae and survival rate; (2) Determine the long-term prospects of patients with MPN and CVT from the aspects of recurrent thrombosis, major bleeding events, neurological sequelae and survival rates Long-term prospects for patients with MPN and CVT;

(3) Identify the significant clinical and laboratory characteristics that distinguish MPN-related CVT from COVID vaccine-related CVT
.

(3) Identify the significant clinical and laboratory characteristics that distinguish MPN-related CVT from COVID vaccine-related CVT
.

(3) Identify the significant clinical and laboratory characteristics that distinguish MPN-related CVT from COVID vaccine-related CVT

Table 1: Clinical and laboratory characteristics and results of 74 patients with cerebral venous thrombosis (CVT) and myeloproliferative tumor (MPN) Table 1: 74 patients with cerebral venous thrombosis (CVT) and myeloproliferative tumor (MPN) The clinical and laboratory characteristics and results ofTable 1:

The specific frequency of the disease is 1.
3% (39/2893), 1.
2% (21/1811) and 0.
2% (3/1888), the essential ones are thrombocythemia, polycythemia vera and primary myelofibrosis respectively
.

Cerebral venous thrombosis occurred before (n= 20, 27%), (n= 32, 44%), or after (n= 22) MPN diagnosis

The specific frequency of the disease is 1.

Table 2: The clinical and laboratory characteristics presented and the results of 42 casesAnd cerebral venous thrombosis (CVT) and myeloproliferative disease (MPN) Table 2: The clinical and laboratory features presented and the results of 42 casesTable 2: Cerebral Vein Thrombosis (CVT) and Myeloproliferative Disease (MPN) Table 2:

 

A total of 72% of patients have headaches
.

Central nervous system bleeding in 10 patients (14%) involved the transverse sinus (51%), sagittal sinus (43%), and sigmoid sinus (35%)

A total of 72% of patients have headaches

The treatment of CVT includes systemic anticoagulation alone (  n   =27) or combined with aspirin (  n   =24), cytoreductive therapy (  n   =14) or both (  n   =   9) )

The current research clarifies the CVT associated with MPN and emphasizes its relationship with the CVT associated with MPN, and emphasizes its  close association with JAK2 V617F, younger age, and women

Original source:

Gangat, N ,  Guglielmelli, P ,  the Betti, S .

Gangat, N ,  Guglielmelli, P ,  the Betti, S .
, Et Al  Cerebral venous Thrombosis and myeloproliferative neoplasms: A Three-Center Study of 74 consecutive Cases .
  Am J Hematol .
  2021 ;  96 (  12 is ):  1580 -  1586 DOI:.
10.
1002 /ajh.
26336 Leave a message here